Special Issue "Medicinal Chemistry in Europe"
Deadline for manuscript submissions: closed (31 January 2019)
This Special Issue is entitled “Medicinal Chemistry in Europe”. In Europe, many research groups, both from industry and academia, are working on medicinal chemistry topics that cover almost all therapeutic fields, ranging from anticancer and antimicrobial agents to compounds potentially active in severe cerebral pathologies, including Parkinson’s and Alzheimer’s diseases. Molecules devoted to the treatment of rare disease are also being investigated. The results obtained, frequently very important and recognized all over the world, are derived from the close collaboration of experts in different areas, such as computational chemistry, organic chemistry, biology, biochemistry and pharmacology.
Scientists from Europe are cordially invited to contribute original research papers or reviews to this Special Issue of Molecules, which reports on the design, synthesis, and evaluation of potentially-active compounds in the different subjects of medicinal chemistry.
Prof. Dr. Silvia Schenone
* Silvia Schenone is a full professor of medicinal chemistry at the Pharmacy Department of the University of Genoa, Italy. She is involved in the design, synthesis and identification of organic molecules endowed with pharmacological activity. She is also interested in structural studies of biological macromolecules and molecular modeling applications in medicinal subjects. She started her work in the field of anti-inflammatory agents, then moved to adenosine receptor antagonists, and in the last few years she has been working on the design and synthesis of protein kinase inhibitors as anticancer agents. Her research on this last topic has led to the publication of 85 articles and four patents. Her other expertise is related to ADME (adsorption, distribution, metabolism and excretion) studies in silico, in vitro and in vivo. In many cases, to improve the bioavailability of the most active compounds, she has prepared and optimized different pharmaceutical formulations, including albumin nanoparticles, liposomes and cyclodextrine complexes. Recently, she has been involved in the synthesis of prodrugs which are particularly useful to improve the bioavailability of active compounds with poor water solubility, as in the case of the majority of protein kinase inhibitors. She collaborates with many groups of biologists and pharmacologists in Italy, Europe and USA. She is the author of 162 articles and of 6 patents.
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug discovery
- biologically active compounds
- anticancer agents
- antimicrobial agents
- analgesic and anti-inflammatory agents
- CNS pathologies
- rare diseases
- cardiovascular diseases